Adamas Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference
October 27 2015 - 4:05PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that
Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of
Adamas Pharmaceuticals, Inc., will present at the Credit Suisse
Healthcare Conference in Scottsdale, Arizona on Tuesday, November
10, 2015 at 8:30 a.m. Mountain Time.
The presentation will be webcast live from the investor
relations section of the Adamas website at
http://ir.adamaspharma.com/events.cfm and available for replay
until December 10, 2015.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical
company driven to improve the lives of those affected by chronic
disorders of the central nervous system. The company seeks to
achieve this by modifying the pharmacokinetic profiles of approved
drugs to create novel therapeutics for use alone and in fixed-dose
combination products. Adamas is currently developing
ADS-5102, its lead wholly-owned product candidate, for the
treatment of levodopa-induced dyskinesia (LID) associated with
Parkinson's disease and for the treatment of major symptoms
associated with multiple sclerosis in patients with walking
impairment. The company's portfolio also includes Namzaric™
and Namenda XR®, two approved products with Forest Laboratories
Holdings Limited, an indirect wholly-owned subsidiary of Allergan
plc. Forest is responsible for marketing both products in the
United States under an exclusive license from Adamas. For
more information, please visit www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co.
KGaA.
For questions, please contact:
Susan Lehner
Investor Relations & Corporate Communications
Adamas Pharmaceuticals, Inc.
Phone: 510-450-3567
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jul 2023 to Jul 2024